MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.41
-0.26
-3.39%
After Hours: 7.48 +0.07 +0.94% 19:46 05/25 EDT
OPEN
7.68
PREV CLOSE
7.67
HIGH
7.81
LOW
7.36
VOLUME
735.08K
TURNOVER
0
52 WEEK HIGH
19.32
52 WEEK LOW
7.24
MARKET CAP
573.70M
P/E (TTM)
-2.7222
1D
5D
1M
3M
1Y
5Y
Mizuho Securities Cuts Price Target on Coherus BioSciences to $25 From $30, Reiterates Buy Rating
MT Newswires · 5d ago
Shanghai Junshi cancer therapy approved for new indication in China
China-based Shanghai Junshi Biosciences Co., Ltd (OTCPK:SHJBF) announced on Monday that the Chinese regulators approved its supplemental new drug application ((sNDA)) for anti-PD1 therapy toripalimab allowing its use for the
Seekingalpha · 05/16 13:39
BRIEF-Coherus BioSciences Says Board Increased Size
reuters.com · 05/13 20:55
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, wh...
Benzinga · 05/13 15:55
BRIEF-Coherus BioSciences Appoints Jill O'Donnell-Tormey To Board Of Directors
reuters.com · 05/11 22:28
Shareholders in Coherus BioSciences (NASDAQ:CHRS) have lost 61%, as stock drops 12% this past week
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
Simply Wall St. · 05/11 13:47
Coherus BioSciences Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thur...
GlobeNewswire · 05/10 12:45
--Barclays Lowers Coherus BioSciences Price Target to $15 From $20, Maintains Overweight Rating
MT Newswires · 05/09 10:47
More
No Data
Learn about the latest financial forecast of CHRS. Analyze the recent business situations of Coherus Bioscien through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
71.43%Buy
28.57%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CHRS stock price target is 21.67 with a high estimate of 30.00 and a low estimate of 13.00.
High30.00
Average21.67
Low13.00
Current 7.41
EPS
Actual
Estimate
-0.99-0.74-0.50-0.25
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 280
Institutional Holdings: 89.09M
% Owned: 115.07%
Shares Outstanding: 77.42M
TypeInstitutionsShares
Increased
58
4.60M
New
20
411.20K
Decreased
68
2.61M
Sold Out
37
2.75M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dennis Lanfear
Chief Financial Officer
McDavid Stilwell
Chief Scientific Officer
Vladimir Vexler
Other
Rosh Dias
Other
Thomas Fitzpatrick
Other
Theresa Lavallee
Other
Paul Reider
Lead Director/Independent Director
Mats Wahlstrom
Director
Charlie Newton
Independent Director
Lee Newcomer
Independent Director
Ali Satvat
Independent Director
Mark Stolper
Independent Director
Kimberly Tzoumakas
No Data
No Data
About CHRS
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.

Webull offers kinds of Coherus Biosciences Inc stock information, including NASDAQ:CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.